相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Follicular lymphoma: 2020 update on diagnosis and management
Arnold Freedman et al.
AMERICAN JOURNAL OF HEMATOLOGY (2020)
Analysis of Japanese patients from the AUGMENT phase III study of lenalidomide plus rituximab (R2) vs. rituximab plus placebo in relapsed/refractory indolent non-Hodgkin lymphoma
Koji Izutsu et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2020)
Management of Adverse Events From the Combination of Rituximab and Lenalidomide in the Treatment of Patients With Follicular and Low-Grade Non-Hodgkin Lymphoma
Bruce D. Cheson et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2020)
Combination lenalidomide-rituximab immunotherapy activates anti-tumour immunity and induces tumour cell death by complementary mechanisms of action in follicular lymphoma
Hsiling Chiu et al.
BRITISH JOURNAL OF HAEMATOLOGY (2019)
AUGMENT: A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent Lymphoma
John P. Leonard et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
HEALTH-RELATED QUALITY OF LIFE (HRQoL) IN RELAPSED/REFRACTORY (R/R) INDOLENT NHL IN THE PHASE 3 AUGMENT TRIAL OF RITUXIMAB (R) PLUS LENALIDOMIDE (R2 ) VERSUS R PLUS PLACEBO
J.P. Leonard et al.
HEMATOLOGICAL ONCOLOGY (2019)
AUGMENT: RELAPSED/REFRACTORY INDOLENT NHL PATIENTS WERE MORE SENSITIVE TO NEXT TREATMENT FOLLOWING LENALIDOMIDE/RITUXIMAB (R2 ) THAN RITUXIMAB/PLACEBO
J. Gribben et al.
HEMATOLOGICAL ONCOLOGY (2019)
Subgroup Analyses of Elderly Patients Aged ≥ 70 Years in AUGMENT: A Phase III Randomized Study of Lenalidomide Plus Rituximab (R2) vs Rituximab Plus Placebo (R-Placebo) in Patients with Relapsed/Refractory (R/R) Indolent Non-Hodgkin Lymphoma (iNHL)
Marek Trneny et al.
BLOOD (2019)
Rituximab: a benchmark in the development of chemotherapy-free treatment strategies for follicular lymphomas
R. Karmali et al.
ANNALS OF ONCOLOGY (2018)
Lenalidomide: A Review in Newly Diagnosed Multiple Myeloma as Maintenance Therapy After ASCT
Yahiya Y. Syed
DRUGS (2017)
Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
M. Dreyling et al.
ANNALS OF ONCOLOGY (2016)
Lenalidomide: A Review of Its Continuous Use in Patients with Newly Diagnosed Multiple Myeloma Not Eligible for Stem-Cell Transplantation
Paul L. McCormack
DRUGS & AGING (2015)
Mechanisms of Action of Lenalidomide in B-Cell Non-Hodgkin Lymphoma
John G. Gribben et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Lenalidomide plus rituximab can produce durable clinical responses in patients with relapsed or refractory, indolent non-Hodgkin lymphoma
Joseph M. Tuscano et al.
BRITISH JOURNAL OF HAEMATOLOGY (2014)
Lenalidomide: A Review of its Use in Patients with Transfusion-Dependent Anaemia due to Low- or Intermediate-1-Risk Myelodysplastic Syndrome Associated with 5q Chromosome Deletion
Yahiya Y. Syed et al.
DRUGS (2013)
Lenalidomide A Review of its Use in the Treatment of Relapsed or Refractory Multiple Myeloma
Lesley J. Scott et al.
DRUGS (2011)
Economic Burden of Follicular Non-Hodgkin's Lymphoma
Talia Foster et al.
PHARMACOECONOMICS (2009)
分享论文
